DUBLIN–(BUSINESS WIRE)–The “Method Development and Validation for Assays Supporting Testing of Biologics” conference has been added to ResearchAndMarkets.com’s offering.
This 2-day seminar is designed to offer a broad overview of developing and validating a range of assay methodologies for biologics with specific key analysis of cell culture, assay variability, and DOE.
Biologics continue to be a steadily growing component of the pharmaceutical industry. The advent of large molecule therapeutics requires a different perspective on the assays needed to support development through preclinical and clinical testing.
Specifically, this seminar covers essential concepts related to cell-based potency methods, ELISA, and other methods supporting biologics. In addition to potency methods this seminar addresses immunogenicity methods for preclinical and clinical studies.
The format of the seminar offers an examination of current best practices as well as time to dissect examples of documentation with emphasis on beneficial systems to consider. Scientists who attend this 2-day seminar will gain knowledge that will be beneficial in helping to achieve well-controlled validated methods.
Learning Objectives:
- Understanding the different requirements for small versus large molecules
- Mapping appropriate timelines with decision points
- Designing, developing, optimizing, and validating key methods
- Potency methods, other release and stability methods
- Preclinical and clinical methods
- Use of DOE and statistical analysis
- Handling of critical materials
- Process monitoring concepts
- Assessment of orthogonal methods
- Assessing readiness for validation
- Defining the validation protocol with real-time capture of data analysis
- Maintaining quality through documentation
Who Should Attend:
- Validation Scientists
- QA/QC
- Regulatory Affairs
- Laboratory Managers
- Assay Development Specialists
- Statistician
- CMC Titles
- Bio Assay
Agenda:
Day 1
- Registration Process: 8:30 AM – 9:00 AM
- Session Start Time: 9:00 AM
- Overview of Biologics and Biotechnology
- Differences between small molecule and large molecule therapeutics
- Assays required for biologics
- Timelines
- Regulatory guidances
- GxP in biologics
- Analytical CMC methods and bioassays
- Assays supporting product development, release, and stability
- Portfolio of required assays
- Mechanism of action and potency methods
- Selection of potency-indicating method(s)
- Assay formats/platforms
- Consideration of reagents, endpoints, signal to background
- Standardizing cell culture procedures
- Understanding and managing assay variability
- Overview of feasibility to validation
- Early development – feasibility
- Use of DOE
- Involvement of statisticians
- Development and final development
- Optimizing the assays
- Validation of cell-based methods
Day 2
- Assays supporting preclinical and clinical studies
- Regulatory guidance
- Assay platforms
- Reagents, endpoints, signal to background
- Method development
- Assessing matrix effects
- Method optimization
- Validation parameters
- Incurred sample reanalysis
- Immunogenicity methods
- Screening methods
- Confirmatory methods
- Neutralizing antibody method
- Biomarker validation
- Written procedures (methods, protocols, SOPs)
- Analyst training
- Maintaining quality in-house and in outsourcing
For more information about this conference visit https://www.researchandmarkets.com/r/3hc574
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900